Stockholm, Sweden, August 30, 2022; Today, the 30th of August 2022, Inify
Laboratories AB, org. no. 559345-4431, held an extraordinary general meeting in
Stockholm. Total 31,807,064 shares were represented at the general meeting,
which corresponds to 70.3% of the total shares and votes. The meeting decided,
with the required majority, on all matters in accordance with the board's
previously published proposal. Below follows a summary of the main decisions,
for further details please refer to the notice that is available on the
company's website.

  · Grant Thornton Sweden AB was elected as external auditing company, with
Joakim Södering as auditor in charge, for the period until the end of next
general meeting, Present auditors, Ernst & Young AB, were released from office.
  · Remuneration to the board and auditors was decided according to the
following:
    · Remuneration to the chairman of the board is SEK 300.000.
    · Remuneration to other members of the board, whom are not also main
shareholders, is SEK 200.000.
    · Remuneration to the auditors will be paid against invoicing, approved by
the company.

For more information, please contact CEO Fredrik Palm (fredrik.palm@inify.com)
or visit www.inify.com

About Inify Laboratories AB (publ)

Inify Laboratories provides cancer diagnostics through ultra-modern laboratory
services within histopathology. Fully digital, standardized and AI- supported
workflow is applied to optimize quality and response times, initially for
prostate cancer. The concept is scalable and extendible to other diagnosis. The
company origins from ContextVision and became independent in February 2022. The
company is based in Sweden and listed on Euronext Growth Oslo under the ticker
INIFY.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Click here for more information

© Oslo Bors ASA, source Oslo Stock Exchange